MiRNA as Functional Players in RMS

Created by: Patrizia Gasparini

Rhabdomyosarcoma (RMS), the most common soft tissue sarcoma of childhood and adolescence, is a rare but aggressive malignancy that originates from immature mesenchymal cells committed to skeletal muscle differentiation. Although RMS is, generally, responsive to the modern multimodal therapeutic approaches, the prognosis of RMS depends on multiple variables and for some patients the outcome remains dismal. Further comprehension of the molecular and cellular biology of RMS would lead to identification of novel therapeutic targets. MicroRNAs (miRNAs) are small non-coding RNAs proved to function as key regulators of skeletal muscle cell fate determination and to play important roles in RMS pathogenesis. The purpose of this review is to better delineate the role of miRNAs as a biomarkers or functional leaders in RMS development, so to possibly elucidate some of RMS molecular mechanisms and potentially therapeutically target them to improve clinical management of pediatric RMS.

Table of Content [Hide]

As miRNAs play a crucial role in the development and progression of RMS, the possibility to exploit these molecules as new therapeutic targets in this pediatric tumor should be considered (Figure 1). To this matter, miR-378 over-expression was functionally demonstrated to cause changes in apoptosis, migration and viability through IGF1R down-modulation. Moreover, replacement of miR-378a-3p induces cytoskeleton organization as well as modulation of muscle protein, such as MyoD1, MyoR, desmin and the myosin heavy chain [1]. MiR-183 knockout guinea pigs showed a reduction in tumor cell migration in vitro and stimulation of phosphatase expression in the tumor suppressor gene and tensin homolog (PTEN), which in turn favored the expression of early growth response 1 (EGR1), thus, strengthening the repression of cell migration [2]. Therefore, miR-183 plays an oncogenic role by targeting two tumor suppressor genes, EGR1 and PTEN and miRNA deregulation is crucial to the development of several types of tumors. As for miR-9a, is able to inhibit cell migration and acts directly on E-cadherin [3] .

Ijms 20 05818 g003

Figure 1. miRNAs modulation in RMS carcinogenesis.

To this regard, several approaches that up-regulate or down-regulate miRNAs have been used to characterize and identify the miRNAs involved in the RMS, demonstrating significant efficacy in the treatment of the pathogenesis of RMS following intravenous administration in vivo [4]. In particular, two pre-clinical studies have shown that ectopic expression of miR-206 by lentiviral vectors leads to cell cycle arrest and myogenic differentiation of RMS cells, preventing cell growth in vivo, thanks to inhibition of oncogene expression c-MET[5][6] . Furthermore, experiments with miR-183 knockdown mice led to significant reductions in tumor migration through the direct promotion of EGR1 expression, regulator of cell migration [2] . Re-expression of miR-203 in RMS cells inhibits their proliferation and migration and promotes terminal myogenic differentiation by acting directly on p63 and leukemia inhibitory factor through JAK/STAT (Janus Kinases/Signal Transducer Activator of Transcription Protein) pathway modulation [7] . miR-29 re-expression in mouse model of RMS inhibited tumor growth through stimulation of differentiation mechanisms, suggesting a tumor-suppressor role for this miRNA  . Furthermore, in some studies, RMS growth and proliferation were significantly arrested by miR-450b-5p, strictly regulated by TGF-β1[8]. Huang et al. demonstrated that overexpression of miR-214 was able to inhibit RMS tumor growth both in vitro and in vivo and induced myogenic differentiation by down-modulation of N-Ras [9]

A major weakness of miRNAs modulation studies in RMS is the employment of only commercially available RMS cell lines for in vitro approaches without a further in vitro validation with primary RMS cell lines generated from patients’ surgical specimen. An innovative way to bypass in vitro cell cultures could be the generation of in vivo models such as RMS Patients Derived Xenografts (RMS-PDXs). To date, few works reported the generation of RMS-PDXs, but none of them analyzed the potential of miRNAs in vivo in RMS development or for therapeutic purposes. Most of the functional studies did not consider the microenvironment role in RMS development that could influence cancer cells behavior and aggressiveness. Infiltrating immune cells have a critical and essential role in supporting tumor growth and this aspect should be also investigated to identify novel potential therapeutic targets for RMS management. The generation of innovative therapeutic agents combined miRNAs mimic or inhibitor with liposomes or nanoparticles, which could be a compelling challenge for RMS treatment for the next years. Although all reported data suggests a probable therapeutic role of miRNAs in RMS, unfortunately, the lack of pre-clinical data leaves unexplored such a critical issue that holds great clinical potential for this pediatric disease.

The publication can be found here:https://www.mdpi.com/1422-0067/20/22/5818/htm

References

  1. Francesca Megiorni; Samantha Cialfi; Heather P McDowell; Armando Felsani; Simona Camero; Alessandro Guffanti; Barry Pizer; Anna Clerico; Alessandra De Grazia; Antonio Pizzuti; et al. Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members. BMC Cancer 2014, 14, 880, 10.1186/1471-2407-14-880.
  2. A. L. Sarver; L. Li; Subbaya Subramanian; MicroRNA miR-183 Functions as an Oncogene by Targeting the Transcription Factor EGR1 and Promoting Tumor Cell Migration. Cancer Research 2010, 70, 9570-9580, 10.1158/0008-5472.can-10-2074.
  3. Sorin Armeanu-Ebinger; Delia Herrmann; Michael Bonin; Ivo Leuschner; Steven W. Warmann; Jörg Fuchs; Guido Seitz; Differential expression of miRNAs in rhabdomyosarcoma and malignant rhabdoid tumor. Experimental Cell Research 2012, 318, 2567-2577, 10.1016/j.yexcr.2012.07.015.
  4. Katarzyna Goljanek‑Whysall; Dylan Sweetman; Andrea E. Münsterberg; Katarzyna Whysall; microRNAs in skeletal muscle differentiation and disease. Clinical Science 2012, 123, 611-625, 10.1042/cs20110634.
  5. Riccardo Taulli; Francesca Bersani; Valentina Foglizzo; Alessandra Linari; Elisa Vigna; Marc Ladanyi; Thomas Tuschl; Carola Ponzetto; The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation.. Journal of Clinical Investigation 2009, 119, 2366-78, 10.1172/JCI38075.
  6. Dongsheng Yan; Xiang Da (Eric) Dong; Xiaoyan Chen; Lihua Wang; Chunjing Lu; Jiao Wang; Jia Qu; Lili Tu; MicroRNA-1/206 Targets c-Met and Inhibits Rhabdomyosarcoma Development*. Journal of Biological Chemistry 2009, 284, 29596-29604, 10.1074/jbc.M109.020511.
  7. Yarui Diao; Xing Guo; Lei Jiang; Gang Wang; Chao Zhang; Jun Wan; Yan Jin; Zhenguo Wu; miR-203, a Tumor Suppressor Frequently Down-regulated by Promoter Hypermethylation in Rhabdomyosarcoma*. Journal of Biological Chemistry 2013, 289, 529-539, 10.1074/jbc.M113.494716.
  8. M M Sun; J F Li; L L Guo; H T Xiao; L Dong; F Wang; F B Huang; D Cao; T Qin; X H Yin; et al. TGF-β1 suppression of microRNA-450b-5p expression: a novel mechanism for blocking myogenic differentiation of rhabdomyosarcoma. Oncogene 2013, 33, 2075-2086, 10.1038/onc.2013.165.
  9. Hui-Jie Huang; Jun Liu; Hu Hua; San-En Li; Jin Zhao; Shen Yue; Ting-Ting Yu; Yu-Cui Jin; Steven Y. Cheng; MiR-214 and N-ras regulatory loop suppresses rhabdomyosarcoma cell growth and xenograft tumorigenesis. Oncotarget 2014, 5, 2161-2175, 10.18632/oncotarget.1855.

Cite this article

Patrizia, Gasparini. MiRNA as Functional Players in RMS, Encyclopedia, 2019, v1, Available online: https://encyclopedia.pub/359